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Pulmonary Computed Tomography Predict the Higher
Response Rate of Empirical Antifungal Therapy in
Patients Undergoing Allogeneic Hematopoietic
Stem Cell Transplantation
Yu Ji, Lan-ping Xu, Dai-hong Liu, Yu-hong Chen, Wei Han, Xiao-hui Zhang, Huan Chen,
Yu Wang, Jing-zhi Wang, Kai-yan Liu, Xiao-jun HuangInvasive fungal disease (IFD) is a leading cause of infection-related mortality among patients undergoing
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the mortality of IFD has been de-
creased with empirical antifungal therapy in this population, overtreatment remains a problem, for the per-
sistent or recurrent fever is nonspecific for an IFD. Hence, we explored retrospectively the value of
incorporating serum galactomannan (GM) test and pulmonary high-resolution computed tomography
(HRCT) as predictors for higher response rate of empirical treatment. In our study, all of 124 patients after
allo-HSCTreceived empirical antifungal therapy when the persistent or recurrent fever developed after re-
ceiving broad-spectrum antibiotics. Meanwhile, the levels of serum GM were monitored twice weekly and
pulmonary HRCTwas performed serially. It showed that the response rate of empirical antifungal therapy
was higher in patients with positive results of serum GM tests and/or chest CT scan than that in all patients
(66.1% versus 44.6%, P5.008). Moreover, only 10 of 55 patients with both negative GM tests and pulmonary
HRCTresponded to empirical treatment, and 7 of these 10 patients did not take antifungal agents for pro-
phylaxis. It suggested that these 2 diagnostic tools could not predict patients without adequate Candida pro-
phylaxis well. Thus, we concluded that serum GM assays and pulmonary CT scan could find out patients who
really need empirical antifungal therapy, which resulted in improving the efficiency of the treatment.
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stem cell transplantINTRODUCTION
Invasive fungal disease (IFD) is a common and life-
threatening complication in severely immunocompro-
mised patients undergoing allogeneic hematopoietic
stem cell transplantation (allo-HSCT) [1,2]. With
the widespread use of fluconazole prophylaxis, the
incidence of invasive aspergillosis is becoming to be
predominant in this population and is associated with
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difficult, and delays in initiating effective antifungal
therapy are associated with increased mortality,
empirical antifungal therapy has been regarded as the
standard practice for neutropenic or immunosuppressed
patients with persistent or recrudescent fever despite
receiving broad-spectrum antibiotics [6-8].
However, one big disadvantage of empirical anti-
fungal therapy is the low efficiency of administration
of antifungal agents. It is that many patients, despite
not really being in need of antifungal therapy, will re-
ceive it [9]. In approximately 40% to 50% of neutro-
penic patients at high risk of IFD would receive
empirical antifungal therapy, whereas in these patients
the true incidence of IFD is in the range of 10% to
15% [10].
Pulmonary computed tomography (CT) scan has
been proved to be superior to the chest X-ray for detec-
tion of pulmonary fungal disease, and it was shown that
systematic use of this new technique allowed earlier759
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the assay for detecting galactomannan (GM) for
diagnosis of invasive aspergillosis with U.S. Food and
Drug Administration approval had been extensively
explored [13-15]. Thus, to reduce the incidence of
overtreatment, Maertens et al. [16] designed and dem-
onstrated the feasibility of a preemptive strategy based
on GM test with ELISA and thoracic high-resolution
computed tomography (HRCT) in high-risk neutro-
penic patients with adequate Candida prophylaxis. The
number of patients received antifungal therapy was re-
duced by 78% (from 41 patients to 9 patients). On the
other hand, 1 of 22 cases of IFD was missed with pre-
emptive strategy, and a randomized, controlled study
by Cordonnier et al. [17] demonstrated the incidence
of IFD was higher in the preemptive treatment group
than in the empirical group (9.1% versus 2.7%). More-
over, the empirical treatment could be started earlier
than preemptive strategy, because it would take a few
days for acquiring the results ofGMtests and pulmonary
CT scan. These suggested the empirical therapy was
essential for high-risk patients.
However, factors predicting the outcome of empir-
ical antifungal therapy had not been discussed until
now. So we conducted the retrospective study to ex-
plore the predictive value of incorporating serum GM
test and pulmonary HRCT on the outcome of empiri-
cal treatment in immunocompromised patients, in
order to improve the efficiency of empirical strategy.PATIENTS AND METHODS
Study Population
From July 2005 to June 2008, all patients with sus-
pected IFD within 1 year after allo-HSCT at the Insti-
tute of Hematology, Peking University were enrolled
in our retrospective study. Eligible patients had to
fulfill all of these 3 criteria: (1) signs and symptoms
suggestive of IFD, (2) persistent (.96 hours) or re-
crudescent fever (.38.0C) while receiving broad-
spectrum antibiotics, (3) receipt of antifungal therapy
longer than 1 week. The study protocol was approved
by the Ethics Committee of the hospital, and informed
consent was obtained from all patients.Study Design
All matched or mismatched allo-HSCT recipients
were nursed in isolated rooms with high-efficiency
particulate air (HEPA) filtration from the start of con-
ditioning therapy until stable engraftment had been
achieved. Most patients took fluconazole orally (200
mg once daily) for antifungal prophylaxis until 23
months after HSCT [18], whereas those with a history
of proven or probable IFD during intensive chemo-
therapy received itraconazole orally (200 mg twicea day) for secondary antifungal prophylaxis [19]. The
majority of patients more than 3 months after HSCT
without severe mucositis or graft-versus-host disease
(GVHD) were no longer receiving antifungal prophy-
laxis.
If patients developed a fever with signs and symp-
toms of infection, antibacterial therapy was given em-
pirically in accordance with the guidelines [20], and
a diagnostic workup was started simultaneously, in-
cluding chest X-ray, blood and sputum culture for mi-
crobiological pathogens, and real-time polymerase
chain reaction (PCR) for cytomegalovirus (CMV) de-
tection. Patients with fevers that were unresponsive
to 45 days of broad-spectrum antibiotics or subse-
quently relapsed despite antibiotic treatment, were
suppected of having invasive fungal disease and entered
into our study. At the same time, empirical antifungal
therapy was initiated, and more tests were performed
for finding fungal pathogens, including fungal cultures
of samples from infected sites and direct microscopy
for pathogens with Grocott-Gomori methenamine
silver or acid Schiff stain, serial serum GM tests, and
pulmonary HRCT. The diagnosis of proven, probable,
and possible IFD in these patients was on the basis of the
European Organization for Research and Treatment of
Cancer/Invasive Fungal Infection Cooperative Group
and the National Institute of Allergy and Infectious
DiseaseMycoses StudyGroup (EORTC/MSG) revised
definitions [21].
Antifungal agents administered in empirical ther-
apy, such as intravenous itraconazole, voriconazole,
conventional, or lipid formulation amphotericin B,
or caspofungin were selected by clinicians in our
hospital. These treatments were given according to
standard protocols or manufacturer’s instructions.
Although the results of GM tests were given to the cli-
nicians weekly, the duration of antifungal treatment was
determined according to the patients’ condition and
diagnosis, without reference to the GM tests.
It was supposed that empirical antifungal therapy
given to patients with positive results of GM tests or
pulmonaryHRCTwould havemore chance of success.
Thus, the response rates of empirical antifungal ther-
apy in all patients with suspected IFD and in patients
with positive results of GM tests or chest HRCT
were calculated respectively. By comparing the success
rates of treatment, the role of serumGM test and chest
HRCT as predictors for outcome of empirical strategy
was evaluated.Serum GM Assays and Pulmonary HRCT
As soon as IFI was suspected, serum sampling was
initiated. During the course of empirical antifungal
therapy, serum samples were collected twice weekly
until the patients’ temperature returned to normal
and signs and symptoms of infection disappeared, or
Table 1. Characteristics of Patients in the Study (n 5 124)
Clinical Characteristics Number of Patients (%)
Mean age: years (range) 30.6 (355)
<18 years (%) 14 (11.3)
$18 years (%) 110 (88.7)
Gender (male/female) 78 / 46
Underlying disease
AML 34 (27.4)
ALL 39 (31.5)
CML 34 (2.74)
MDS 8 (6.5)
AMLL 3 (2.4)
MM 3 (2.4)
Other* 3 (2.4)
Type of allo-HSCT
HLA-matched 31 (25.0)
HLA-mismatched 82 (66.1)
Unrelated 11 (8.9)
No. with fever
Neutropenic (%) 76 (61.3)
Nonneutropenic (%) 48 (38.7)
Prophylaxis for IFI
None 38 (30.6)
FLU (oral) 77 (62.1)
ITR (oral) 9 (7.3)
Antifungal therapy
ITR (intravenous) 89 (71.8)
VOR 3 (2.4)
AmB 12 (9.7)
CAS 13 (10.5)
Combination treatment 7 (5.6)
AML indicates acutemyelogenous leukemia; ALL, acute lymphocytic leuke-
mia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome;
AMLL, acute myelogenous lymphocytic leukemia; MM, multiple myeloma;
FLU, fluconazole; ITR, itraconazole; VOR, voriconazole; AmB, amphoteri-
cin B; CAS, caspofungin.
*Other: aplastic anemia (n 5 1), chronic eosinophilic leukemia (n 5 1),
and non-Hodgkin lymphoma (n 5 1).
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stored at 220C and GM assays were performed
weekly with the ELISA kit (Platelia Aspergillus) by
technicians who were unaware of the clinical status
of the patients. The GM index (GMI) was calculated
from the ratio of the optical density (OD) obtained
from the patient serum sample and the control. The
cutoff value in our hospital for Chinese patients under-
going allo-HSCTwith or without neutropenia was de-
fined as 2 consecutive GMI of $0.8 or once of $1.0
according to our previous study [22].
Pulmonary HRCT was performed every 12
weeks if possible, and the positive result was defined
as the presence of 1 of the following 3 signs [21]: (1)
dense, well-circumscribed lesions with or without
a halo sign; (2) air-crescent sign; (3) cavity. The atypi-
cal presentation of invasive aspergillosis, such as
ground glass attenuation, small nodules, etc., were
defined as negative of CT scans.
Evaluation of Antifungal Therapy
The outcome of empirical antifungal therapy was
categorized into 3 levels according to the patients’ tem-
perature and signs and symptoms of infections: (1)
success: if the patient’s temperature returned to nor-
mal, and the signs and symptoms of infection were
cured or improved; (2) failure: if the fever was sustained
or the clinical status was stable or progressed; (3)
ambiguous: if it was hard to decidewhether the antifun-
gal therapy or other concomitant treatment, such as
immunosuppressant or antiviral therapy, was effective.
Analysis
Patient demographics and clinical characteristics
were outlined using descriptive statistics. Univariate
analyses were performed using the 2-group chi-square
test or the Fisher exact test for categorical variables
and the 2-group t-test for continuous variables. A logis-
tic regression model was developed to determine
independent factors associated with the successful out-
come of empirical antifungal therapy, and the results
were reported as odds ratio (OR) with 95% confidence
intervals (CI). A 2-sided P value of\.05 was considered
significant for all comparisons.RESULTS
Patient Characteristics
A total of 124 patients undergoingmatched or mis-
matched allo-HSCTwere enrolled into our retrospec-
tive study. Baseline characteristics are presented in
Table 1. The febrile episodes occurred between 1 and
358 days after allo-HSCT. Neutropenic fever devel-
oped in 76 (61.3%) patients, whereas 48 (38.7%) pa-
tients with fever did not have neutropenia. Among 86patients receiving antifungal prophylaxis, including
77who tookfluconazole orally, and the remaining 9pa-
tients received itraconazole orally, whereas 38 patients
did not take any antifungal prophylaxis. All patients had
1 or multiple risk factors for developing IFD, such as
prolonged neutropenia, severe GVHD, long-term ste-
roid use, or receipt of intensive immunosuppressant
treatment.
Diagnosis of IFD
Among 47 patients with positive results of pul-
monary HRCT indicated for IFD, 28 had the presen-
tation of dense, well-circumscribed lesions with or
without a halo sign, 8 had air-crescent sign, and 11
had cavities in pulmonary lesions. According to chest
CT and culture-based or biopsy techniques, the diag-
nosis of IFD was categorized as 1 proven, 4 probable,
and 44 possible IFD.
As previously reported [22], we have determined
the optimal cutoff value for GM tests in Chinese pa-
tients after allo-HSCT with good sensitivity and spec-
ificity (81.8% and 86.7%, respectively). Five hundred
sixty-eight serum samples were collected from 124 pa-
tients, and the serum GM levels were detected in each
sample by ELISA. Fifty patients had positive results of
762 Biol Blood Marrow Transplant 17:759-764, 2011Y. Ji et al.GM test, whereas the other 74 patients were negative.
Therefore, use of GM test changed EORTC classifica-
tion from possible IFD to probable IFD in 20 patients
for positive GM tests. Thus, the incidence of IFD in
our study population was 20.2% (1 proven and 24
probable IFD in 124 patients).
Outcome of Antifungal Therapy
The overall response rate of empirical antifungal
therapy was 44.6% (50/112), excluding 12 patients
with ambiguous outcome. According to the results of
GM tests and pulmonary HRCT, 118 patients were
divided into 4 groups (Fig. 1), excluding 6 patients re-
ceiving piperacillin/tazobactam within the duration of
screening GM tests because of the probability of false
positives [23]. The response rate in patients with pos-
itive results of GM tests and/orHRCTwas 66.1% (39/
59), which was significantly higher than that in all
patients (P 5 .008).
It was notable that only 10 of 59 patients (20.4%)
with both negative results of GM test and chest
CT scan responded to empirical antifungal therapy.
Among these 10 patients, 1 was diagnosed with proven
IFD for his blood culture yielded Candida albicans and
Candida glabrata, but the other 9 patients could not
reach the EORTC/MSG criteria of possible IFD.118 patients with persisten
excluding 6 patients with posi
piperacillin/ta
21 probable IA 
(3 IA-related 
death) 
2 possible IFD 
(2 IFD-related 
death) 
GM(+)
CT(+)
21 patients 
GM(+)
CT(-)
23 patients
17 success 
4 failure 
0 ambiguous 
(81.0%)
12 success 
10 failure 
1 ambiguous 
(54.5%)
Antifungal therapy (
Diagnosis according to EO
Figure 1. Outcome of antifungal therapy in subgrouEight of these 9 patients were not neutropenic, includ-
ing 7 not taking antifungal agents for prophylaxis.
Seven had ground-glass attenuation on the chest
HRCT, and 2 had no lesions. Among patients with
both negative results of GM tests and HRCT, the suc-
cess rates of empirical antifungal therapy in patients
with or without fluconazole were 6.5% (2/31) and
43.8% (7/16), respectively (P5 .003), and those in pa-
tients with or without neutropenia were 16.1% (5/31)
and 27.8% (5/18), respectively (P 5 .465).
Factors Predict Success in Empirical Therapy
In our retrospective study, univariate analysis was
performed in 108 patients with definite outcomes to
explore which factors were associated with the success
outcome of empirical antifungal therapy in immuno-
compromised patients undergoing allo-HSCT. These
factors included: types of HSCT (P5 .454), antifungal
prophylaxis (P5 .089), neutropenia (P5 .733), serum
GM tests (P\ .001), pulmonary HRCT (P\ .001),
and antifungal agents (P5 .346). Moreover, multivari-
able logistic regression demonstrated that positive re-
sult of HRCT (OR, 6.35; 95% CI, 2.3817.00) and
serum GM tests (OR, 3.73; 95% CI, 1.519.23)
were independently associated with the success out-
come of empirical antifungal therapy. Prophylaxist or recrudescent fever, 
tive GM test for receiving 
zobactam
19 possible IFD 
(all alive) 
1 proven IFD 
54 no IFD 
(all alive) 
GM(-)
CT(+)
19 patients
GM(-)
CT(-)
55 patients 
10 success 
6 failure 
3 ambiguous 
(62.5%)
response rates) 
RTC/MSG criteria 
10 success 
39 failure 
6 ambiguous 
(20.4%)
ps according to GM test and pulmonary HRCT.
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creased the efficacy of the empirical treatment (OR,
0.33; 95% CI, 0.130.87).DISCUSSION
Because persistent or recurrent fever is not spe-
cific for IFD in immunocompromised patients after
allo-HSCT [6,9], the overuse of antifungal agents is
inevitable if they are given empirically. In the present
study, the higher response rate of empirical treatment
in patients with positive results of GM test and/or
chest CT scan compared to patients with both
negative suggested GM test and CT scan were 2 good
predictors for successful outcome, possibly because of
the high incidence of invasive aspergillosis. In the
recent decade, Aspergillus has become the predominant
fungal pathogen in patients after allo-genetic HSCT
[24], especially taking fluconazole for Candida prophy-
laxis. In our population, the most patients were infected
with IA. It was reasonable that serum GM test and
chest HRCT were suitable as predictors for response
of empirical antifungal therapy.However, a few patients
with both negative results ofGM tests andCT scanwho
were not receiving fluconazole for prophylaxis re-
sponded to antifungal treatment, and the antifungals
wereeffective to spp.Candida, it implied that the success-
ful outcome inpatientswith bothnegative results ofGM
test and CT scan mostly because of infection with
Candida. Although the response rate of 6.5% in patients
with taking fluconazole showed the empirical antifungal
should be stopped early in these patients, especially
when the signs and symptoms of infection were not
improved after receiving empirical antifungal therapy.
Besides fungal pathogens, the false negative should
be another potential reason interfering with the pre-
dictive value. The cutoff value of GM test was a critical
factor for the sensitivity and specificity. Although 2
consecutive GM indices$0.5 had been recommended
as the appropriate cutoff value in Europe and America
in recent years [25], 0.8 (2) or 1.0 were used instead in
our institute [22], for it would remain the good sensi-
tivity and specificity in Chinese immunocompromised
patients after allogeneic HSCT with or without neu-
tropenia. Actually, if the cutoff value of 0.5 (2) was
used, the response rates of empirical antifungal therapy
were similar between patients with positive and nega-
tive results of GM tests (51.2% versus 47.0%, P 5
.559), so it could not notably distinguish patients
with invasive aspergillosis from suspected IFD patients
in our population.
Other factors affect the performance of GM test
should also be considered. Marr et al. [14] reported
that receipt of mold-active prophylaxis and empirical
antifungal therapy might decrease sensitivity of GM
test; thus, we found incorporating chest HRCT wasessential to predict the success of empirical treatment.
The 62.5% of response rate in cases with negative GM
test and positive chest CT scan suggested the HRCT
was also valuable for identifying patients with real
IFD [26]. Nonneutropenia was another reason of false
negative ofGM tests, which could also affect the predic-
tive power. As our retrospective analysis on cases with
negative GM test, the success rates in patients with neu-
tropenia was a little lower than that in patients without
neutropenia (25.6% versus 38.5%, P 5 .273), which
suggest the predictive value of GM test was lower for
patients without neutropenia.
On the other hand, the predictive value of GM test
might be interfered with false-positive results, such as
certain antibiotics, milk-based diet, etc. [13,14]. In our
analysis, 6 patients with positive result of GM test were
omitted, because of receiving piperacillin/tazobactam
concomitantlym, and the data showed 3 of them had
normal chest HRCT and did not response to the
empirical antifungal therapy.
Itraconazolewas themajor antifungal agent admin-
istered empirically in our institute, which was another
characteristic of our study. The response rate of empir-
ical antifungal therapy with intravenous itraconazole
were 43.8% (35/80), whichwas similar to that with am-
photericin B (50.0%, 6/12, P5 .685), and those was in
accordance with other research of empirical antifungal
therapy [27].
In summary, serum galactomannan assay with
ELISA and pulmonary HRCT are good predictors for
the higher probability of success outcome of empirical
antifungal therapy. Both negative results of GM tests
and pulmonary CT scans suggested the probability of
IFD was little and the empirical treatment could be
ceased early if the patient’s clinical status was not
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